跳至主要内容
临床试验/NCT00067938
NCT00067938已完成4 期

Lamictal for Use in Treatment of Bipolar Disorder In Adults. A Practical Clinical Assessment of Tolerability and Clinical Effectiveness.

GlaxoSmithKline1 个研究点 分布在 1 个国家目标入组 1,200 人开始时间: 2003年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
1,200
试验地点
1
主要终点
The primary endpoint will be the rate of rash during 12 weeks.

研究概览

简要总结

Bipolar study of tolerability, clinical response and patient satisfaction

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of bipolar I disorder.
  • Must be on a stable regimen of psychiatric medication for at least 2 months prior to study.
  • If female, must not be pregnant, or must be incapable of conceiving or be taking steps to prevent conception.

排除标准

  • Patients with a clinically significant psychiatric or physiologic comorbidity including significant substance abuse, depression or mania which is of an unstable of progressive nature that could interfere in participation of this study.
  • Presence of untreated thyroid disease.
  • Patient is actively suicidal or homicidal.
  • Patient has history of severe hepatic or renal insufficiency.
  • Patient is currently participating in another clinical trial.

研究组 & 干预措施

Arm 1

Other

Open label single arm study

干预措施: lamotrigine (Drug)

结局指标

主要结局

The primary endpoint will be the rate of rash during 12 weeks.

时间窗: 12 Weeks

次要结局

  • Change from baseline in Week 5 and Week 12 Clinical Global Impression-Bipolar version (CGI-BP) Severityand Improvement scores.(12 Weeks)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验